

**ASX ANNOUNCEMENT****11 October 2022****Cann Group sleep study enrolment target met**

---

**11 October 2022** – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) announced today that it has met its enrolment target for the Company’s Phase III clinical trial of low-dose Satipharm CBD capsules for short-term sleep disturbance. In excess of 212 patients have been enrolled into the clinical trial, which commenced recruitment in February at trial centres in both Australia and New Zealand.

The Company, in conjunction with its trial investigators, is now undertaking a follow-up analysis to determine if the participant numbers are adequate to detect statistical significance and provide a definitive study outcome.

The Company anticipates that a favourable trial result will support the registration of Satipharm CBD capsules as a Schedule 3 over-the-counter medicine in Australia, making it available to patients without requiring a prescription. Cann Group will update the market with the results of the trial once they have been completed and analysed.

Global healthcare company, Haleon, previously secured an exclusive evaluation and option agreement with Cann Group for the marketing and sale of over-the-counter Satipharm CBD capsules in Australia. The clinical study report is a pivotal milestone in progressing towards a definitive commercial agreement with Haleon.

Cann Group’s CEO, Peter Crock, said, “We are pleased to have reached this milestone with our medicine registration strategy. Recruiting participants for clinical trials has become more difficult following COVID, so we are happy to report that this study is proceeding well, and we look forward to sharing the results in the coming months.”

**Authorised for release by the Board of Directors of Cann Group Limited.**

**For all media enquiries please contact:**

Rhys Cohen  
Senior Corporate Communications Manager  
+61 449 679 095  
[rhys.cohen@canngrouponlimited.com](mailto:rhys.cohen@canngrouponlimited.com)

**For all other information please contact:**

Peter Crock  
CEO  
Cann Group Limited  
+61 3 9095 7088  
[contact@canngrouponlimited.com](mailto:contact@canngrouponlimited.com)

Deborah Ambrosini  
CFO  
Cann Group Limited  
+61 3 9095 7088  
[deborah.ambrosini@canngrouponlimited.com](mailto:deborah.ambrosini@canngrouponlimited.com)

**About Cann Group**

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has built world-class research, cultivation and GMP manufacturing facilities in Melbourne, and a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

**Learn more at:** [www.canngrouponlimited.com](http://www.canngrouponlimited.com) | [www.satipharm.com](http://www.satipharm.com)